share_log

8-K: Current report

8-K: Current report

8-K:重大事件
美股SEC公告 ·  05/21 17:16

Moomoo AI 已提取核心信息

180 Life Sciences Corp. has announced that it is facing delisting from The Nasdaq Stock Market due to non-compliance with the minimum stockholders' equity requirement. The company was initially notified by Nasdaq on November 15, 2023, and was given until May 13, 2024, to regain compliance. Failing to meet the requirement, the company received a delisting determination letter on May 14, 2024, with a suspension of trading set to commence on May 23, 2024. However, 180 Life Sciences has appealed the decision, and the delisting action has been stayed pending a final decision by the Nasdaq Hearings Panel. The company plans to present a compliance plan at the Panel hearing. In the meantime, trading of the company's common stock and public warrants will continue on Nasdaq under the...Show More
180 Life Sciences Corp. has announced that it is facing delisting from The Nasdaq Stock Market due to non-compliance with the minimum stockholders' equity requirement. The company was initially notified by Nasdaq on November 15, 2023, and was given until May 13, 2024, to regain compliance. Failing to meet the requirement, the company received a delisting determination letter on May 14, 2024, with a suspension of trading set to commence on May 23, 2024. However, 180 Life Sciences has appealed the decision, and the delisting action has been stayed pending a final decision by the Nasdaq Hearings Panel. The company plans to present a compliance plan at the Panel hearing. In the meantime, trading of the company's common stock and public warrants will continue on Nasdaq under the symbols 'ATNF' and 'ATNFW'. The company acknowledges that there is no assurance that its plan will be accepted or that it will be able to regain compliance with Nasdaq's listing requirements. The potential delisting could negatively impact the company's stock and warrant prices, its ability to raise capital, and could trigger defaults and penalties under existing agreements.
180 生命科学公司宣布,由于不遵守最低股东权益要求,它正面临从纳斯达克股票市场退市。纳斯达克最初于2023年11月15日通知该公司,并获准在2024年5月13日之前恢复合规。由于未能满足要求,该公司于2024年5月14日收到退市决定书,暂停交易定于2024年5月23日开始。但是,180 Life Sciences已对该决定提出上诉,除名行动已暂停,等待纳斯达克听证小组的最终决定。该公司计划在小组听证会上提交合规计划。同时,该公司的普通股和公开认股权证将继续在纳斯达克交易,交易代码为 “ATNF” 和 “ATNFW”。该公司承认,无法保证其计划会被接受,也无法保证其能够重新遵守纳斯达克的上市要求。潜在的退市可能会对公司的股票和权证价格及其筹集资金的能力产生负面影响,并可能触发现有协议规定的违约和处罚。
180 生命科学公司宣布,由于不遵守最低股东权益要求,它正面临从纳斯达克股票市场退市。纳斯达克最初于2023年11月15日通知该公司,并获准在2024年5月13日之前恢复合规。由于未能满足要求,该公司于2024年5月14日收到退市决定书,暂停交易定于2024年5月23日开始。但是,180 Life Sciences已对该决定提出上诉,除名行动已暂停,等待纳斯达克听证小组的最终决定。该公司计划在小组听证会上提交合规计划。同时,该公司的普通股和公开认股权证将继续在纳斯达克交易,交易代码为 “ATNF” 和 “ATNFW”。该公司承认,无法保证其计划会被接受,也无法保证其能够重新遵守纳斯达克的上市要求。潜在的退市可能会对公司的股票和权证价格及其筹集资金的能力产生负面影响,并可能触发现有协议规定的违约和处罚。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息